About
Yangtze values licensing activities as an essential part of the Group’s growth strategy. Pan-Pacific Biopharma represents Yangtze overseas to search and evaluate new pharmaceutical products and advanced technology for achieving mutual development and commercial success with our partners.
We are actively searching for innovative drugs at late stage (after Phase II and has obtained POC) as well as cutting-edge technology platforms including pharmaceutical preparation techniques and drug delivery system.
We are flexible in terms of collaboration models. In-licensing, co-development, supply and distribution, and other models are all welcome to discuss.
If you would like to initiate a conversation with Yangtze / Pan-Pacific Biopharma, please feel free to contact us at BD@yangtzeriver.com.

• Regulatory affairs
  Successfully registered over 300 products in highly regulated environment.
  Know-how and experience in Registration, pricing, tendering, hospital listing, reimbursement.
  Over 10 generic products obtained separate pricing.
• Clinical research
  Interactive conversations with SFDA to maximize the efficiency of conducting clinical studies in China.
• Distribution & Sales network
  Over 5,000 sales representatives in 31 provinces in China.
  Cover 6,800 hospitals – the total number of class 3 and class 2 hospitals in China
  High bargaining power with hospitals.
• Sales force
  Different from a great number of Chinese pharma that use local agents and dealers to distribute, Yangtze has 100%
  internal sales team to ensure effective management and standard promotion.
  Strict and structured sales training.
  High employee loyalty and well-designed reward incentive programs.
• Sales
  Well balanced product portfolio: 70% by small molecules, 30% by TCM. They span over infection, gastro-intestinal
  diseases, cardio-vascular diseases, oncology, and the other therapeutic areas.
  Distribution channels: #5 in hospital sales, #10 in retail pharmacy sales (2011)
  Broad geographic coverage: Two-way strategy to ensure sales growth in both urban regions and rural areas. Yangtze is
  also ranked #1 in county/town-level hospital drug sales according to IMS.
• Corporate Image
  Enjoys reputation as “a national pharmaceutical brand” with high quality and responsibility.